Retatrutide hits the same receptor, so the same concern applies
Its multifaceted action and impressive efficacy have led to a surge of interest in its application for weight loss
(2024), who observed that Tirzepatide 15 mg had a more significant impact on weight reduction compared to subcutaneous Semaglutide
PT-141 is the clear winner for anyone seeking an evidence-based peptide for sexual function, with FDA approval, defined dosing, and a characterized safety profile
for example, reduced kidney function can extend elimination to 7 to 10 weeks, and real-world data show that 20% of patients discontinue semaglutide due to gastrointestinal side effects, which can cause abrupt timing changes
Editors note: This report has been updated to reflect findings from the TRIUMPH-1 clinical trial released on May 21, 2026 by Eli Lilly and Company.